Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services (NCT00203970)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research is to gain insight into the way in which physicians adopt new practice techniques. In particular, we are interested in how medical innovations diffuse throughout social networks. We wish to examine the diffusion of Low Molecular Weight Heparin (LMWH) use for Deep Vein Thrombosis (DVT) throughout the social network of general internal medicine interns, residents, and attendings at the University of Chicago Hospital. In numerous clinical trials, LMWH has been demonstrated to be as effective as unfractionated heparin as a bridge to long-term anticoagulation therapy with Coumadin, with the added benefit of early discharge from the hospital with easy dosing, no need for monitoring, and home therapy. A DVT critical pathway was established at the U of C in 1998, and LMWH was used off-label for that purpose beginning in 1997. However, it is unclear how quickly the use of LMWH was adopted by the physicians on the general medicine services, or whether there exists a pattern for this adoption.
Who can join: Review the eligibility criteria below.
Location: The University of Chicago — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
- Observation (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- The University of Chicago — Chicago, Illinois
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Thrombosis
- Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization — Boston, Massachusetts
- Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT — Portland, Oregon
- Pharmacogenomics of Warfarin in Hispanics and Latinos — Tucson, Arizona
- Platelet Volunteers, Longitudinal and Multi-omic Study — Bethesda, Maryland
Explore by condition: All Thrombosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.